VTRS

Viatris Inc

Healthcare


Presented:12/19/2023
Price:$10.39
Cap:$12.46B
Current Price:$11.84
Cap:$14.13B

Presented

Date12/19/2023
Price$10.39
Market Cap$12.46B
Ent Value$29.15B
P/E Ratio6.89x
Book Value$17.09
Div Yield4.62%
Shares O/S1,199.67M
Ave Daily Vol8,937,854
Short Int3.09%

Current

Price$11.84
Market Cap$14.13B
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Publicly traded companies mentioned herein: Pfizer Inc (PFE), Viatris Inc (VTRS)

Highlights

The presenter is long shares of Viatris Inc (VTRS), which has seen its stock price consistently trend downward for the better part of a decade. The business has suffered from a weak management team, as well as industry headwinds in its US generics business following its 2020 merger with Pfizer’s Upjohn. However, it seems that VTRS is turning a corner with a new management team, a more diversified business mix, improved secular trends, and a divestiture plan that could drive significant deleveraging and capital return. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.